Hypoxia in Breast Cancer—Scientific Translation to Therapeutic and Diagnostic Clinical Applications

Breast cancer has been the leading cause of female cancer deaths for decades. Intratumoral hypoxia, mainly caused by structural and functional abnormalities in microvasculature, is often associated with a more aggressive phenotype, increased risk of metastasis and resistance to anti-malignancy treat...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 11; p. 652266
Main Authors Zhang, Ying, Zhang, Hongyi, Wang, Minghong, Schmid, Thomas, Xin, Zhaochen, Kozhuharova, Lora, Yu, Wai-Kin, Huang, Yuan, Cai, Fengfeng, Biskup, Ewelina
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 11.03.2021
Subjects
biomarkers
breast cancer
hypoxia
hypoxia-induced factors
hypoxia-related treatment
Oncology
oxidative stress
hypoxia
biomarkers
hypoxia-related treatment
breast cancer
precision medicine
hypoxia-induced factors
oxidative stress
Online AccessGet full text

Cover

More Information
Summary:Breast cancer has been the leading cause of female cancer deaths for decades. Intratumoral hypoxia, mainly caused by structural and functional abnormalities in microvasculature, is often associated with a more aggressive phenotype, increased risk of metastasis and resistance to anti-malignancy treatments. The response of cancer cells to hypoxia is ascribed to hypoxia-inducible factors (HIFs) that activate the transcription of a large battery of genes encoding proteins promoting primary tumor vascularization and growth, stromal cell recruitment, extracellular matrix remodeling, cell motility, local tissue invasion, metastasis, and maintenance of the cancer stem cell properties. In this review, we summarized the role of hypoxia specifically in breast cancer, discuss the prognostic and predictive value of hypoxia factors, potential links of hypoxia and endocrine resistance, cancer hypoxia measurements, further involved mechanisms, clinical application of hypoxia-related treatments and open questions.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Xiaosong Chen, Shanghai Jiao Tong University, China
These authors have contributed equally to this work
This article was submitted to Women's Cancer, a section of the journal Frontiers in Oncology
Reviewed by: Gong Cheng, Harvard University, United States; Inbar Nardi Agmon, Rabin Medical Center, Israel
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2021.652266